BACKGROUND: We compared the efficacy and toxicity of oral capecitabine and continuous infusion of 5-fluorouracil (5-FU) in the preoperative chemoradiation treatment of patients with rectal cancer. PATIENTS AND METHODS: The files of 89 patients with rectal cancer, 43 treated preoperatively with oral capecitabine and 46 with intravenous 5-FU, were reviewed, and the outcome of the groups was compared. RESULTS: There was no statistically significant difference in the complete pathological response rate between the capecitabine and the 5-FU groups (30% vs. 17%, P = 0.15). The downstaging rate was higher in the capecitabine group (77% vs. 50%, P = 0.009). Toxicity was mild in both groups. The rate of Grade 3 gastrointestinal toxicity was similar in the two groups (diarrhea 2% vs. 4%, proctitis 5% vs. 7%), except for one patient in the 5-FU group (2%) who developed a rectovaginal fistula. In the capecitabine group, one patient (2%) had Grade 3 hand-foot syndrome, and another had an acute myocardial infarction. In the 5-FU group, two patients (4%) had Grade 3 hematological toxicity, and three (6%) had complications from Port-a-Cath insertion. CONCLUSION: Preoperative chemoradiation with oral capecitabine appears to be safe and well tolerated, and at least as good as continuous 5-FU. Copyright 2006 Wiley-Liss, Inc.
BACKGROUND: We compared the efficacy and toxicity of oral capecitabine and continuous infusion of 5-fluorouracil (5-FU) in the preoperative chemoradiation treatment of patients with rectal cancer. PATIENTS AND METHODS: The files of 89 patients with rectal cancer, 43 treated preoperatively with oral capecitabine and 46 with intravenous 5-FU, were reviewed, and the outcome of the groups was compared. RESULTS: There was no statistically significant difference in the complete pathological response rate between the capecitabine and the 5-FU groups (30% vs. 17%, P = 0.15). The downstaging rate was higher in the capecitabine group (77% vs. 50%, P = 0.009). Toxicity was mild in both groups. The rate of Grade 3 gastrointestinal toxicity was similar in the two groups (diarrhea 2% vs. 4%, proctitis 5% vs. 7%), except for one patient in the 5-FU group (2%) who developed a rectovaginal fistula. In the capecitabine group, one patient (2%) had Grade 3 hand-foot syndrome, and another had an acute myocardial infarction. In the 5-FU group, two patients (4%) had Grade 3 hematological toxicity, and three (6%) had complications from Port-a-Cath insertion. CONCLUSION: Preoperative chemoradiation with oral capecitabine appears to be safe and well tolerated, and at least as good as continuous 5-FU. Copyright 2006 Wiley-Liss, Inc.
Authors: C Grávalos; P García-Alfonso; R Afonso; V Arrazubi; A Arrivi; J C Cámara; J Capdevila; A Gómez-España; A Lacasta; J L Manzano; M Salgado; J Sastre; E Díaz-Rubio Journal: Clin Transl Oncol Date: 2011-12 Impact factor: 3.405
Authors: Manpreet Bedi; Prajnan Das; John M Skibber; Miguel A Rodriguez-Bigas; George J Chang; Cathy Eng; Robert A Wolff; Nora A Janjan; Sunil Krishnan; Christopher H Crane Journal: Gastrointest Cancer Res Date: 2007-03
Authors: Geke A Hospers; Cornelis J A Punt; Margot E Tesselaar; Annemieke Cats; Klaas Havenga; Jan W H Leer; Corrie A Marijnen; Edwin P Jansen; Han H J M Van Krieken; Theo Wiggers; Cornelis J H Van de Velde; Nanno H Mulder Journal: Ann Surg Oncol Date: 2007-07-26 Impact factor: 5.344
Authors: Javier Gallego-Plazas; Francisco Menarguez-Pina; Natividad Martinez-Banaclocha; Vanesa Pons-Sanz; Fernando Mingol-Navarro; Jose A Ruiz-Macia; Sonia Macia-Escalante Journal: Int Semin Surg Oncol Date: 2008-07-14